Nakamura K, Akiyama K, Makino I
Second Department of Internal Medicine, Asahikawa Medical College.
Nihon Shokakibyo Gakkai Zasshi. 1995 Jan;92(1):62-71.
The effect of ursodeoxycholic acid (UDCA) treatment for more than one year on chronic hepatitis in regard to responder and non-responder and influence of UDCA administration on serum bile acid metabolism were studied. All of non-responders (16 patients) were hepatitis B or C patients, and seven of fifteen responders were negative for hepatitis B and C virus marker and could be considered autoimmune hepatitis. These patients got drastic improvement of liver function test, anti-nuclear antibody in five patients and anti-smooth muscle antibody in three patients were decreased. Although HAI scores for liver pathology before UDCA treatment were not different between responders and non-responders, the intralobular necrosis was improved in responders after UDCA treatment. Concerning serum bile acid analysis, total bile acid and UDCA concentration in responders were lower than non-responders. Percentage of iso-ursodeoxycholic acid in responders was significantly higher than non-responders. These results suggest the effectiveness of UDCA therapy on autoimmune hepatitis.
研究了熊去氧胆酸（UDCA）治疗一年以上对慢性肝炎的疗效，区分了应答者和无应答者，并研究了UDCA给药对血清胆汁酸代谢的影响。所有无应答者（16例患者）均为乙型或丙型肝炎患者，15例应答者中有7例乙型和丙型肝炎病毒标志物呈阴性，可被视为自身免疫性肝炎。这些患者的肝功能检查有显著改善，5例患者的抗核抗体和3例患者的抗平滑肌抗体下降。尽管UDCA治疗前应答者和无应答者的肝脏病理HAI评分无差异，但UDCA治疗后应答者的小叶内坏死有所改善。关于血清胆汁酸分析，应答者的总胆汁酸和UDCA浓度低于无应答者。应答者中异熊去氧胆酸的百分比显著高于无应答者。这些结果表明UDCA疗法对自身免疫性肝炎有效。
